Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Research output: Contribution to journal › Article
The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||BMC Clinical Pathology|
|Publication status||Published - 2015|
No data available